[go: up one dir, main page]

AR069349A1 - Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular - Google Patents

Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular

Info

Publication number
AR069349A1
AR069349A1 ARP080105006A ARP080105006A AR069349A1 AR 069349 A1 AR069349 A1 AR 069349A1 AR P080105006 A ARP080105006 A AR P080105006A AR P080105006 A ARP080105006 A AR P080105006A AR 069349 A1 AR069349 A1 AR 069349A1
Authority
AR
Argentina
Prior art keywords
eye
trpv1
treatment
pain
amg
Prior art date
Application number
ARP080105006A
Other languages
English (en)
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Publication of AR069349A1 publication Critical patent/AR069349A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan métodos para tratar los síntomas del ojo seco mediante la administracion de inhibidores del canal cationico del potencial receptor transitorio, subfamilia V, miembro 1 (TRPV1). También se divulgan métodos para prevenir o aliviar el dolor ocular mediante la administracion de inhibidores de TRPV1. Reivindicacion 2: El método de la reivindicacion 1 en el cual la cantidad farmacéuticamente efectiva del antagonista de TRPVI es 0,001-5,0% (p/v). Reivindicacion 4: El método de la reivindicacion 1 en el cual la composicion se administra en el ojo de manera topica. Reivindicacion 5: El método de la reivindicacion 1 en el cual el ojo seco está asociado con la cirugía refractiva. Reivindicacion 6: El método de la reivindicacion 1, en el cual el antagonista de TRPV1 es AMG-517 o AMG-628. Reivindicacion 10: El método de la reivindicacion administra en el ojo de manera topica.
ARP080105006A 2007-11-19 2008-11-18 Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular AR069349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98890107P 2007-11-19 2007-11-19

Publications (1)

Publication Number Publication Date
AR069349A1 true AR069349A1 (es) 2010-01-13

Family

ID=40253888

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105006A AR069349A1 (es) 2007-11-19 2008-11-18 Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular

Country Status (4)

Country Link
US (1) US20090131449A1 (es)
AR (1) AR069349A1 (es)
TW (1) TW200927192A (es)
WO (1) WO2009067438A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505908A (ja) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ Ｔｒｐｖ１アンタゴニスト
TW201020236A (en) * 2008-10-17 2010-06-01 Abbott Lab TRPV1 antagonists
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
WO2012134943A1 (en) 2011-03-25 2012-10-04 Abbott Laboratories Trpv1 antagonists
JP6202400B2 (ja) * 2011-12-12 2017-09-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 核酸に関連した眼疾患を治療するための組成物および方法
WO2013096223A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP7096152B2 (ja) 2015-10-06 2022-07-05 オーラ・インコーポレーテッド 一過性受容体電位カチオンチャネルサブファミリーｍメンバー８（ｔｒｐｍ８）拮抗薬及び使用方法
JOP20210217A1 (ar) * 2019-02-15 2023-01-30 Novartis Ag طرق لعلاج ألم سطح عين
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR20220078604A (ko) * 2019-10-04 2022-06-10 센주 세이야꾸 가부시키가이샤 헤테로시클리덴아세트아미드 유도체 함유 의약

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4939135A (en) * 1988-10-03 1990-07-03 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) * 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
AU2462097A (en) * 1996-10-04 1998-04-24 Alcon Laboratories, Inc. The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels

Also Published As

Publication number Publication date
US20090131449A1 (en) 2009-05-21
WO2009067438A1 (en) 2009-05-28
TW200927192A (en) 2009-07-01

Similar Documents

Publication Publication Date Title
AR069349A1 (es) Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
BRPI0821683B8 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
EA201690033A3 (ru) Морфинановые соединения
MX383688B (es) Derivados de piridona amida como agonistas de canales de sodio nav1. 8 y el uso de los mismos en el tratamiento de dolor.
MX2012004848A (es) Compuestos heterociclicos triciclicos.
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
EA201000046A1 (ru) Замещенные имидазогетероциклы
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
DOP2011000354A (es) Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MX2024000828A (es) Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis.
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma

Legal Events

Date Code Title Description
FB Suspension of granting procedure